Adoption of Serogroup B Meningococcal Vaccine Recommendations.
Adoption of Serogroup B Meningococcal Vaccine Recommendations.
复制标题
DOI：
10.1542/peds.2018-0344
复制
发表时间：
2018-09
期刊：
影响因子：
8
通讯作者：
Albert AP
中科院分区：
文献类型：
--
作者：
Kempe A;Allison MA;MacNeil JR;O'Leary ST;Crane LA;Beaty BL;Hurley LP;Brtnikova M;Lindley MC;Albert AP
2015年，ACIP建议16-23奥尔兹可以根据个人临床决策接种血清群B脑膜炎球菌（MenB）疫苗（B类）。在美国儿科医生（Peds）和家庭医生（FPs）中评估：1）关于MenB疫苗接种的实践; 2）影响推荐疫苗决定的因素; 3）与16-18岁常规访视时讨论MenB疫苗相关的因素。我们从2016年10月至12月通过电子邮件和互联网调查了具有全国代表性的儿科和FP样本。有效率为72%（660/916）。在常规访视期间，51%的儿科和31%的FP报告总是/经常讨论MenB疫苗。在经常/总是讨论的人中，91%的人建议接种疫苗;在从不/很少讨论的人中，11%的人建议接种疫苗。73%的儿科和41%的FP目前接种了MenB疫苗。虽然许多提供者报告不知道影响推荐决定的因素，但血清型B脑膜炎球菌病爆发（89%），疾病发病率（62%）和有效性（52%），安全性（48%）和MenB疫苗的保护期（39%）增加了推荐的可能性，而类别B建议（45%）降低了可能性。那些稍微/完全不知道MenB疫苗的人[风险比0.32（95% CI 0.25-0.41）]和那些在HMO工作的人[0.39（0.18-0.87）]的可能性较小，而那些知道他们所在州疾病爆发的人[1.25（1.08-1.45）]更有可能开始讨论MenB疫苗。初级保健医生在关于血清群B脑膜炎球菌病和MenB疫苗的知识方面存在重大差距，这似乎是决定不讨论疫苗的主要驱动因素。
In 2015, ACIP recommended 16–23 year olds may be vaccinated with serogroup B meningococcal (MenB) vaccine based on individual clinical decision-making (Category B). To assess among US pediatricians (Peds) and family physicians (FPs): 1) practices regarding MenB vaccine delivery; 2) factors influencing a decision to recommend vaccine; 3) factors associated with discussing MenB vaccine at 16–18 year-old routine visits. We surveyed a nationally representative sample of Peds and FPs by e-mail and internet from 10–12/2016. The response rate was 72% (660/916). During routine visits, 51% of Peds and 31% of FPs reported always/often discussing MenB vaccine. Among those who discussed often/always, 91% recommended vaccination; among those who never/rarely discussed, 11% recommended. 73% of Peds and 41% of FPs currently administered MenB vaccine. While many providers reported not knowing about factors influencing recommendation decisions, serogroup B meningococcal disease outbreaks (89%), disease incidence (62%), and effectiveness (52%), safety (48%), and duration of protection of MenB vaccine (39%) increased likelihood of recommending while the Category B recommendation (45%) decreased likelihood. Those somewhat/not at all aware of MenB vaccine [Risk Ratio 0.32 (95% CI 0.25–0.41)] and those practicing in an HMO [0.39 (0.18–0.87)] were less likely whereas those aware of disease outbreaks in their state [1.25 (1.08–1.45)] were more likely to initiate a discussion about MenB vaccine. Primary care physicians have significant gaps in knowledge about serogroup B meningococcal disease and MenB vaccine and this appears to be a major driver of the decision not to discuss the vaccines.
登录
查看更多内容
影响因子：
5.5
作者：
Davis, Matthew M.;Broder, Karen R.;Clark, Sarah J.
通讯作者：
Clark, Sarah J.
影响因子：
7.6
作者：
Dempsey, Amanda F.;Cowan, Anne E.;Clark, Sarah J.
通讯作者：
Clark, Sarah J.
影响因子：
8
作者：
Kempe, Allison;Babbel, Christine;Dickinson, L. Miriam
通讯作者：
Dickinson, L. Miriam
DOI：
10.3122/jabfm.18.1.13
发表时间：
2005-01-01
期刊：
JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE
影响因子：
--
作者：
Oster, NV;Mcphillips-Tangum, CA;Howell, K
通讯作者：
Howell, K
影响因子：
3.1
作者：
Nelson, Noele P.;Allison, Mandy A.;Kempe, Allison
通讯作者：
Kempe, Allison